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Abstract 
Review on ADCYAP1, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: PACAP 
HGNC (Hugo): ADCYAP1 
Location: 18p11.32 
Local order: 
The PACAP gene has 5 exons. 
Note: PACAP-27 or PACAP-38 are secreted 
proteins which binds to membrane G-protein 
coupled receptors (GPCR) increasing intracellular 
cAMP signaling. 
DNA/RNA 
Note 
The ADCYAP1 gene encodes 5 exons and is 
localized to chromosome 18p11 (Kimura et al., 
1990). Exons 1 and 2 encode for the 5'UTR and the 
signal peptide. Exon 3 encodes for the N-terminal of 
pro-PACAP upstream from PRP. PRP is encoded by 
Exon 4. Exon 5 encodes for the C-terminal of pro-
PACAP including PACAP-27, PACAP-38 and the 
3'UTR (Vaudry et al., 2009). 
Description 
The PACAP gene which contains 7230 bases is 
highly conserved in nature (Sherwood et al., 2000). 
Transcription 
The gene transcript is 2.7 kb (Ghatei et al., 1993). 
Protein 
Note 
Pituitary adenylate cyclase-activating polypeptide 
(PACAP) was isolated from ovine hypothalamus and 
contains 38 amino acids.  
PACAP-38 elevates cAMP in rat pituitary cells in 
culture (Miyata et al., 1989).  
PACAP-27 was isolated from ovine hypothalamus 
and had the same N-terminal 27 amino acids as does 
PACAP-38 (Miyata et al., 1990).  
PACAP-27 has high homology with vasoactive 
intestinal peptide (VIP) and moderate homology 
with PRP.  
The PACAP-38 amino acid sequence is identical in 
mammals.  
PACAP has a β-turn at residues 9-12, followed by an 
α-helix at residues 12-14, 15-20 and 22-24 (Inooka 
et al., 1992). PACAP binds with high affinity to 3 
GPCR (VPAC1, VPAC2 and PAC1) which are 
members of the class II or class B secretin-like 
receptors (Harmar et al., 2012).  
The activated VPAC1, VPAC2 or PAC1 interacts 
with a stimulatory guanine nucleotide binding 
protein (Gs) increasing adenylylcyclase activity 
resulting in elevated cAMP (Arimura et al., 1992). 
The increased cAMP activates protein kinase (PK) A 
causing phosphorylation of various proteins such as 
CREB leading to altered gene expression (Moody et 
al., 2003).  
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Structure of human prepro-PACAP. Human prepro-PACAP (1-176) is metabolized by signal proteases to generate pro-PACAP 
(26-176). Pro-PACAP is metabolized by pro-hormone convertases to (26-79), big PACAP-related peptide (82-129; PRP) and 
PACAP-38. Pro-PACAP (26-176) can be further metabolized to PRP (82-109) and PACAP-27 by other enzymes. 
PACAP is derived from the 176 amino acid precursor protein prepro-PACAP. Initially the signal peptide (1-25) is cleaved by 
signal proteases to generate pro-PACAP (26-176). Pro-PACAP is metabolized by pro-hormone convertases and 
carboxypeptidases to (26-79), (82-129) and (132-170). The C-terminal peptides (132-170) and (132-159) are metabolized to by 
peptidylglycine alpha-amidating monooxygenase enzymes to PACAP-38 and PACAP-27, respectively, which have amidated C-
terminals. 
 
 
In addition, PAC1 interacts with Gq causing 
phosphatidylinositol (PI) turnover (Pisegna and 
Wank, 1996). The resulting metabolites inositol-
1,4,5-trisphosphate and diacylglycerol increases 
cytosolic calcium and activates protein kinase C, 
respectively. 
Expression 
PACAP is produced in neurons within the adrenals, 
brain, gastrointestinal (GI) tract, pituitary and testis 
(Ghatei et al., 1993). Addition of PACAP to adrenal 
chormaffin cells causes catecholamine release 
(Watanabe et al., 1990). High densities of PACAP 
are present in the hypothalamus and PACAP as well 
as glutamate shift the circadian rhythm in the 
suprachiasmatic nucleus (Vaudry et al., 2009). In the 
gastrointestinal tract PACAP stimulates the 
secretion of saliva, gastric acid, bicarbonate and 
peptides leading to myorelaxation (Moody et al., 
2011). In PACAP knockout mice or mice treated 
with PACAP(6-38) there is reduced insulin secretion 
after glucose challenge (Shintani et al., 2003). In 
pituitary cells, PACAP elevates cAMP increasing 
the secretion of LH, GH, PRL, ACTH and TSH 
(Vaudry et al., 2009). The results indicate that 
PACAP is present in the normal CNS and periphery. 
Localisation 
Prepro-PACAP is stored in dense core 
neurosecretory granules in cells. In cellular extracts 
approximately an order of magnitude more PACAP-
38 is detected than PRP or PACAP-27. PACAP-38 
and PACAP-27 have approximately an order of 
magnitude more biological activity than does PRP 
(Fahrenkrug, 2010). PACAP is metabolized by 
neutral endopeptidase and has a half life of 5 min. 
Function 
PACAP alters neurotransmitter release in the CNS, 
causes increased insulin and histamine secretion in 
the periphery, controls vasodilation, bronchodilation 
alters intestinal motility and stimulates cellular 
proliferation as well as differentiation (Vaudry et al., 
2009). 
Homology 
VIP has 67% sequence homology with PACAP-27. 
The sequence for PACAP-38 is identical in 
mammals (Fahrenkrug, 2010). 
Mutations 
Note 
Sequence mutations of PACAP-38 are rare. 
Numerous mutations of PAC1 have been reported 
including deletions, which affect PACAP binding 
(PAC1 short; PAC1 very short) and splice variants, 
which affect signal transduction (hip, hop1, hop2; 
Blechman and Levkowitz, 2013). SNP rs2267735 of 
PAC1 is associated with post-traumatic stress 
disorder (PTSD) in females (Ressler et al., 2011). 
Implicated in 
Lung cancer 
PACAP-38 immunoreactivity is higher in the human 
lung cancer than normal lung biopsy specimens 
(Szanto et al., 2012). PAC1 is present in lung cancer 
cells and PACAP(6-38) inhibits their proliferation 
(Zia et al., 1995). PACAP-27 may stimulate lung 
cancer proliferation as a result of EGFR 
transactivation (Moody et al., 2012). 
Breast cancer 
A 19.9 kDa prepro-PACAP was detected in human 
breast cancer biopsy specimens (Garcia Fernandez et 
al., 2004). PACAP-27 stimulated and PACAP(6-38) 
inhibited the growth of breast cancer cells (Leyton et 
al., 1999). 
Colon cancer 
PACAP knockout mice but not wild type mice 
develop colitis and colorectal tumors after treatment  
with dextran sulfate sodium (Nemetz et al., 2008). 
PACAP-38 stimulates the growth of colon cancer 
cells (Le et al., 2002). 
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Pheochromocytoma 
PACAP increases the cAMP after addition to PC12 
adrenal pheochromocytoma cells (Watanabe et al., 
1990) and causes catecholamine secretion (Taupenot 
et al., 1999). PACAP addition to PC12 cells 
increases their survival as a result of Trk receptor 
tyrosine kinase phosphorylation and activation of 
Akt (Rajagopal et al., 2004). 
Pituitary adenoma 
PACAP inhibits apoptosis caused by TGFβ addition 
to human pituitary adenoma cells (Oka et al., 1999). 
PAC1 receptor mRNA was present in all pituitary 
adenoma cells except prolactnomas (Oka et al., 
1998). 
Medulloblastoma 
Disruption of a single copy of the PACAP gene 
increased medulloblastoma incidence in ptc1 mutant 
mice 2.5-fold (Lelievre et al., 2008). 
Diabetes 
ADCYAP1 stimulates insulin secretion in a glucose-
dependent manner (Filipsson et al., 2001). Two 
SNPs g.9863G>A, G54D in exon 3, and 
g.12712C>G in exon 5 were found in European type 
2 diabetic patients (Gu et al., 2002). 
Neuronal survival 
PACAP stimulates neurite outgrowth and enhances 
neuronal cell survival (Canonico et al., 1996). 
PACAP addition to rat cerebellar neurites increases 
cAMP and inhibits caspase-3 activity (Vaudry et al., 
2009). 
Schizophrenia 
In PACAP knockout mice and schizophrenic 
patients, brain strathmin I is up-regulated 
(Hashimoto et al., 2007). PACAP reduces Strathmin 
I in animal models of schizophrenia by inhibiting the 
association of the DISCI-binding zinc-finger protein 
with DBZ (Katayama et al., 2009). 
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